Impact of prior cancer history on survival in patients with adenocarcinoma of esophagogastric junction: a retrospective cohort study using SEER database

Read full text Summarise with VIRAT
Authors: Hongkun Lai, Jianlong Zhou, Jiabin Zheng, Huolun Feng, Lixue Cao, Baohua Hou, Yong Li
Cited by: 0
References: 38

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: The exclusion of patients with prior malignancies from clinical trials remains controversial, yet its prognostic impact on adenocarcinoma of esophagogastric junction (AEG) is poorly characterized. This retrospective cohort study aimed to evaluate the prevalence and survival implications of prior cancer in AEG patients, providing evidence for refining trial eligibility criteria. Methods: The Surveillance, Epidemiology, and End Results databases were used to collect data between 1975 and 2021, and 10,895 AEG patients were included in the study. Inclusion required histologically confirmed AEG with complete follow-up data and only those with one prior cancer preceding the index AEG diagnosis to ensure temporal clarity. Prior cancers were classified according to their primary site, frequency, stage, and timing. Survival analyses included Kaplan-Meier curves, multivariate Cox regression, and competing risk models (Fine and Gray’s). Propensity score matching was applied as a sensitivity analysis to validate the robustness of the primary findings. Results: Among 10,895 eligible patients, 16.58% (n=1,806) had prior cancer history and a median age of 67 years, with 79.20% male patients. The cohort showed significantly different overall survival (median 13 months for prior cancer vs. 16 months for no prior cancer). Disease stage distribution was: localized (18.40%), regional (28.80%), distant (29.30%), and unstaged (23.50%). The most common types of prior cancer were prostate (28.07%), and colon and cecum (11.13%). Additionally, 38.7% of the prior tumors were staged localized disease at prior cancer diagnosis. The median time period between detection of first and subsequent malignancies was 6.0 years. Patients with prior cancer were older (median age: 73 vs. 67 years) and had higher rates of localized AEG (23.30% vs. 17.50%, P

Fields of Study & Subjects

Multiple and Secondary Primary Cancers Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes

Publication details

Journal / source
Translational Cancer Research
Volume
15
Issue
3
Pages
188–188
Publication date
1 March 2026
Language
EN